Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development« Back to News
Further validates efficiency of AlivaMab Mouse for antibody drug discovery and development
SAN DIEGO, Calif. – November 5, 2018 – Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced that a therapeutic antibody candidate discovered using the AlivaMab Mouse platform entered clinical development in 2018. Additional therapeutic antibody candidates discovered using the AlivaMab Mouse platform are currently in late-stage preclinical development.
“Advancement of an AlivaMab antibody into clinical development a few short years after our partners started using AlivaMab Mouse for drug discovery represents another milestone in the ongoing validation of the AlivaMab Mouse platform”, said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The AlivaMab Mouse continues being recognized by our partners as the best-in-class platform for the discovery and development of therapeutic antibody candidates. We are gratified by the expanding pipeline of clinical-stage antibodies, which we expect to have a positive impact on patients in the coming years.”
Ablexis and AlivaMab Discovery Services, LLC will be presenting a webinar on the options for generating human therapeutic antibodies, taking a holistic view of the impact of platform selection on the entire discovery and development continuum. Dr. Green and John “Lippy” Lippincott, Ph.D. will describe the pros and cons of the different approaches and discuss key factors to consider when evaluating and using platforms. Click here to register for this free webinar, scheduled for Thursday, November 8th at noon ET, 9am PT.
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at email@example.com.